All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AR-15512
Therapeutic Area: Ophthalmology Product Name: AVX012
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The COMET-1 trial is a randomized, double-masked, vehicle-controlled trial evaluating the efficacy and safety of AR-15512 (TRPM8 agonist) in patients with dry eye disease. AR-15512 is a TRPM8 agonist for the treatment of patients with dry eye disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ciclosporin
Therapeutic Area: Ophthalmology Product Name: OTX-CSI
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
Subjects treated with OTX-CSI demonstrated an improvement in signs of DED and an improvement in symptoms of Dry Eye Disease. OTX-CSI is a cyclosporine intracanalicular insert for the treatment of dry eye disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ciclosporin
Therapeutic Area: Ophthalmology Product Name: OTX-CSI
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The Phase 2 clinical trial is a U.S.-based, randomized, masked, multi-center trial evaluating two different formulations of OTX-CSI with vehicle insert in approximately 105 subjects who will be followed for a period of 16 weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Risuteganib
Therapeutic Area: Ophthalmology Product Name: Luminate
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: $50.0 million Upfront Cash: $10.0 million
Deal Type: Agreement September 21, 2020
Details:
The agreement provides Bausch with global rights for risuteganib, Allegro's lead investigational compound in retina, including Other ophthalmology assets such as Allegro's ALG-1007, a topical integrin regulator under investigation for the treatment of dry eye disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegcetacoplan
Therapeutic Area: Ophthalmology Product Name: APL-2
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
This new analysis of the FILLY study demonstrates that pegcetacoplan impacts the progression of nascent GA,1,2 the earlier stage of disease that precedes atrophy, in areas of the retina outside of GA lesions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Razuprotafib
Therapeutic Area: Ophthalmology Product Name: AKB-9778
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2020
Details:
The study is designed to evaluate the safety and efficacy of a topical ocular formulation of razuprotafib in approximately 195 patients followed over a 28-day period, and patients must undergo a 28-day washout prior to randomization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RGX-314
Therapeutic Area: Ophthalmology Product Name: RGX-314
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Regenxbio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2020
Details:
REGENXBIO has dosed the first patient in its Phase 2 clinical trial to evaluate the suprachoroidal delivery of RGX-314, an adeno-associated virus (AAV) gene therapy, using Clearside’s SCS Microinjector® for the treatment of wet age-related macular degeneration (wet AMD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RGX-314
Therapeutic Area: Ophthalmology Product Name: RGX-314
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Company declared clearance of the Investigational New Drug (IND) application by the U.S. FDA to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy. The IND is active, and REGENXBIO plans to begin dosing patients in a Phase II trial, ALTITUDE.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NRO-1
Therapeutic Area: Ophthalmology Product Name: NRO-1
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
Details:
NRO-1 is a novel therapeutic with the potential to regenerate corneal nerves in ophthalmic diseases. The Phase 2 study is a multicenter, randomized, double-masked, vehicle-controlled trial that evaluates the safety and efficacy of NRO-1 in patients with dry eye disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IC 265
Therapeutic Area: Ophthalmology Product Name: IC 265
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Ophthalmology Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 28, 2020
Details:
The exclusive license is for ophthalmic indications in China and other countries of Southeast Asia. The agreement will accelerate the development of IC 265 and IC 270 in both China and the U.S.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
